| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| June 2, 2026 | ±3.1% | -1.2% | over-priced |
| August 28, 2025 | ±1.9% | -0.6% | over-priced |
| May 29, 2025 | ±2.5% | +1.1% | over-priced |
| December 5, 2024 | ±3.4% | -1.7% | over-priced |
| August 29, 2024 | ±2.4% | +0.2% | over-priced |
| November 30, 2023 | ±1.7% | +1.4% | over-priced |
| August 24, 2023 | ±3.4% | -3.5% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2027 | $7.74 | $3.2B | $340M |
| Q4 FY2026 | — | $0 | $0 |
| Q2 FY2026 | $5.78 | $2.8B | $261M |
| Q1 FY2026 | $6.70 | $2.8B | $305M |
Ulta Beauty, Inc. Common Stock (ULTA) reports in 149 days, with the next report estimated for November 9, 2026. Across the last 7 reports, options priced an average ±2.6% earnings move while the stock actually moved 1.4% on average — the market has systematically over-priced ULTA's earnings risk. Fundamentals into the print: EPS down 8.0% year-over-year, revenue down 9.3%. QuantLogix's live 5-factor engine currently reads ULTA as a neutral at 39/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →